Research News for March 2011
1–9 of 9 articles
-
MRI Better at Detecting Cancer Earlier in Women with Abnormal Breast Cancer Gene
New research has found that women with an abnormal breast cancer gene screened with MRI were less likely to be diagnosed with advanced-stage breast cancer compared to being screened with other tests.
-
Older Women Diagnosed with DCIS or Early-Stage Disease Have Excellent Prognosis
A large study found that women older than 67 diagnosed with either DCIS or stage I breast cancer were just as likely to be alive 10 years after diagnosis as women not diagnosed with breast cancer.
-
Tamoxifen Effectively Lowers Breast Cancer Risk in High-Risk Women Younger Than 55
An analysis of four large studies found that tamoxifen effectively reduces breast cancer risk in women younger than 55 at high risk. This benefit outweighed the costs and potential side effects of treatment.
-
FDA Approves Generic Taxotere
The FDA has approved a generic form of Taxotere, which may lower treatment costs.
-
Chemo, Hormonal Therapy May Increase Risk of Falling
Research suggests that women who get chemotherapy or hormonal therapy to treat early-stage breast cancer are more likely to fall than women the same age who don't get those treatments.
-
Avastin Slows Growth of Metastatic Breast Cancer
Women diagnosed with metastatic breast cancer who got Avastin in combination with chemotherapy lived 1 to 3 months longer without the cancer growing compared to women who only got chemotherapy, but overall survival was the same for both groups.
-
Smoking Increases Breast Risk in Postmenopausal Women
Cigarette smoking — either past or present — and exposure to second-hand smoke increase breast cancer risk in postmenopausal women.
-
Halavan May Help Treat Metastatic Disease
Women diagnosed with metastatic breast cancer that didn't respond to other treatments who got Halavan lived 2 months longer than women who got supportive care or a standard metastatic cancer treatment.
-
Herceptin After Surgery Reduces Recurrence Risk of HER2-Positive, Early-Stage Disease
New research shows women diagnosed with early-stage, HER2-positive breast cancer who were treated with adjuvant chemotherapy then Herceptin for 1 year were 24% less likely to have the cancer come back compared to women who got adjuvant chemotherapy but no Herceptin.
1–9 of 9 articles
